Perjeta (Pertuzumab) vs Kadcyla (trastuzumab emtansine)
Perjeta (Pertuzumab) vs Kadcyla (trastuzumab emtansine)
Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) are both targeted therapies used to treat HER2-positive breast cancer, but they work in different ways. Perjeta is designed to prevent the HER2 protein from pairing with other HER receptors on the surface of cancer cells, which can block cell signaling and growth, and is often used in combination with chemotherapy and another HER2-targeted drug, Herceptin (trastuzumab). Kadcyla, on the other hand, is a combination of Herceptin and a chemotherapy drug, which allows for the direct delivery of chemotherapy to the HER2-positive cancer cells, potentially reducing the impact on healthy cells. The choice between these medications would depend on the specific characteristics of the cancer, previous treatments, and the patient's overall health, and should be made in consultation with an oncologist.
Difference between Perjeta and Kadcyla
Metric | Perjeta (Pertuzumab) | Kadcyla (trastuzumab emtansine) |
---|---|---|
Generic name | Pertuzumab | Trastuzumab emtansine |
Indications | HER2-positive breast cancer | HER2-positive breast cancer |
Mechanism of action | HER2 dimerization inhibitor | Antibody-drug conjugate targeting HER2 receptors |
Brand names | Perjeta | Kadcyla |
Administrative route | IV infusion | IV infusion |
Side effects | Diarrhea, hair loss, nausea | Fatigue, liver toxicity, nausea |
Contraindications | Hypersensitivity to pertuzumab | Hypersensitivity to trastuzumab emtansine or its excipients |
Drug class | Monoclonal antibody | Antibody-drug conjugate |
Manufacturer | Genentech (Roche) | Genentech (Roche) |
Efficacy
Efficacy of Perjeta (Pertuzumab) in Breast Cancer
Perjeta (pertuzumab) is a monoclonal antibody that targets the HER2 receptor, a protein that can promote the growth of cancer cells. In the treatment of breast cancer, Perjeta is specifically used for the treatment of HER2-positive breast cancer, which is a type of breast cancer that tests positive for human epidermal growth factor receptor 2 (HER2), indicating a higher aggressiveness and a poorer prognosis. When used in combination with trastuzumab and chemotherapy, Perjeta has been shown to significantly improve overall survival and progression-free survival in patients with HER2-positive metastatic breast cancer. The efficacy of Perjeta in the neoadjuvant setting (before surgery) has also demonstrated an increase in the percentage of patients who experience a complete pathological response, meaning there is no residual invasive cancer detectable in the breast tissue and lymph nodes.
Efficacy of Kadcyla (Trastuzumab Emtansine) in Breast Cancer
Kadcyla (trastuzumab emtansine) is an antibody-drug conjugate that combines the HER2 targeting properties of trastuzumab with the chemotherapy agent DM1 (emtansine). Kadcyla is designed to deliver the chemotherapy directly to HER2-positive cancer cells, thereby minimizing exposure to healthy cells. It is approved for use in patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and a taxane, separately or in combination. Studies have shown that Kadcyla significantly extends both progression-free and overall survival in these patients compared to standard therapies. Additionally, Kadcyla has been approved as adjuvant therapy for HER2-positive early breast cancer in patients who have residual invasive disease after neoadjuvant treatment, where it has been shown to improve invasive disease-free survival.
Comparative Efficacy in the Treatment of Breast Cancer
Both Perjeta and Kadcyla have been instrumental in the treatment of HER2-positive breast cancer, although they are used at different stages of the disease and in different combinations. Perjeta is often used in combination with trastuzumab and chemotherapy in the first-line setting for metastatic disease and in the neoadjuvant setting, while Kadcyla is typically used as a single agent in the adjuvant setting or for patients with metastatic disease who have previously received trastuzumab and a taxane. The choice between Perjeta and Kadcyla depends on several factors, including the stage of cancer, prior treatments, and the presence of residual disease after neoadjuvant therapy.
Conclusion
In conclusion, Perjeta and Kadcyla are both effective treatments for HER2-positive breast cancer, a particularly aggressive form of the disease. Their use has improved outcomes for patients with this subtype of breast cancer, extending survival times and increasing the rates of complete pathological responses. The specific application of each drug is determined by the patient's individual disease characteristics and treatment history. Ongoing research continues to refine the use of these drugs to maximize their efficacy and improve the prognosis for patients with HER2-positive breast cancer.
Regulatory Agency Approvals
Perjeta
Kadcyla
Access Perjeta or Kadcyla today
If Perjeta or Kadcyla are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us